Acquired disorders of platelet function

Platelets

Volumn , Issue , 2007, Pages 1051-1076

  Rao, A Koneti ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56749165528     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50820-X     Document Type: Chapter

References (413)

1. Mielke C.H., Kaneshiro M.M., Maher I.A., et al. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969, 34:204-215.
2. Mielke C.H. Influence of aspirin on platelets and the bleeding time. Am J Med 1983, 74:72-78.
3. Boccardo P., Remuzzi G., Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004, 30:579-589.
4. Himmelfarb J., Holbrook D., McMonagle E., et al. Increased reticulated platelets in dialysis patients. Kidney Int 1997, 51:834-839.
5. Steiner R.W., Coggins C., Carvalho A.C. Bleeding time in uremia: A useful test to assess clinical bleeding. Am J Hematol 1979, 7:107-117.
6. Livio M., Gotti E., Marchesi D., et al. Uraemic bleeding: Role of anemia and beneficial effect of red cell transfusions. Lancet 1982, 2:1013-1015.
7. Moia M., Mannucci P.M., Vizzotto L. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987, 8570:1227-1229.
8. Castillo R., Lozano T., Escolar G., et al. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 1986, 68:337-342.
9. Gralnick H.P., McKeown L.P., Williams S.B., et al. Plasma and platelet von Willebrand's factor defects in uremia. Am J Med 1988, 85:806-810.
10. Salvati F., Liani M. Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs 2001, 24:131-135.
11. Escolar G., Cases A., Bastida E., et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 1990, 73:1336-1340.
12. Benigni A., Boccardo P., Galbusera M., et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993, 22:668-676.
13. Joist J.H., George J.N. Hemostatic abnormalities in liver and renal disease. Hemosasis and thrombosis: Basic principles and clinical practice 2001, 955-973. Lippincott, Philadelphia. 4th ed. R.W. Colman, J. Hirsh, V.J. Marder (Eds.).
14. Sreedhara R., Itagaki I., Hakim R.M. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996, 27:355-364.
15. Kozek-Langenecker S.A., Masaki T., Mohammad H., et al. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int 1999, 56:299-305.
16. Rao A.K., Carvalho A. Acquired qualitative platelet defects. Hemostasis and thrombosis: Basic principles and clinical practice 1994, 685-704. Lippincott, Philadelphia. 3rd ed. R.W. Colman, J. Hirsh, V.J. Marder (Eds.).
17. Knudsen F., Nielsen A.H., Kristensen S.D. The effect of dialyser membrane material on intradialytic changes in platelet count, platelet aggregation, circulating platelet aggregates, and antithrombin III. Scand J Urol Nephrol 1985, 19:227-232.
18. Guzzo J., Niewiarowski S., Musial J., et al. Secreted platelet proteins with anti-heparin and mitogenic activities in chronic renal failure. J Lab Clin Med 1980, 16:102-112.
19. Green D., Santhanam S., Krumlovsky F.A., et al. β-Thromboglobulin in patients with chronic renal failure: Effect of hemodialysis. Thromb Haemost 1979, 41:416.
20. Kubisz P., Parizek M., Seghier F., et al. Relationship between platelet aggregation and plasma β-thromboglobulin levels in arteriovascular and renal disease. Atherosclerosis 1985, 55:363-368.
21. DiMinno G., Martinez J., McKean M.L., et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985, 79:552-559.
22. Remuzzi G.D., Marchesi M., Livio A.E., et al. Altered platelet and vascular prostaglandin-generation in patients with chronic renal failure and prolonged bleeding times. Thromb Res 1978, 13:1007-1115.
23. Remuzzi G., Benigni A., Dodesini P., et al. Reduced thromboxane formation in uremia: Evidence for functional cyclooxygenase-defect. J Clin Invest 1983, 71:762-768.
24. Rao A.K. Uraemic platelets. Lancet1 1986, 913-914.
25. Vecino A.M., Teruel J.L., Navarro J.L., et al. Phospholipase A2 activity in platelets of patients with uremia. Platelets 2002, 13:415-418.
26. Lubbecke F., Sandlebaum J., Schutterle G., et al. Adenylate cyclase and α-2 adrenoreceptors in thrombocytes of chronic uremic patients. Blood Purif 1988, 6:269-275.
27. Ware J.A., Clark B.A., Smith M., et al. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood 1989, 73:172-176.
28. Castaldi P.A., Rozenberg M.C., Stewart J.H. The bleeding disorder of uraemia. Lancet 1966, 2:66-69.
29. Diaz-Ricart M., Estebanell E., Cases A., et al. Abnormal platelet cytoskeletal assembly in hemodialyzed patients results in deficient tyrosine phosphorylation signaling. Kidney Int 2000, 57:1905-1914.
30. Horowitz H.I., Cohen B.D., Martinez P., et al. Defective ADP-induced platelet factor 3 activation in uremia. Blood 1967, 30:331-340.
31. Rabiner S.F., Hrodek O. Platelet factor 3 in normal subjects and patients with renal failure. J Clin Invest 1968, 47:901-912.
32. Horowitz H.I., Stein I.M., Cohen B.D., et al. Further studies on the platelet inhibitory effect of guanidinosuccinic acid: Its role in uremic bleeding. Am J Med 1970, 49:336-345.
33. Noris M., Remuzzi G. Uremic bleeding: Closing the circle after 30 years of controversies?. Blood 1999, 94:2569-2574.
34. Noris M., Benigni A., Boccardo P., et al. Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993, 44:445-450.
35. Hogman M., Frostell C., Arnberg H., et al. Bleeding time prolongation and NO inhalation. Lancet 1993, 341:1664-1665.
36. Gries A., Bode C., Peter K., et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation 1998, 97:1481-1487.
37. Matsumoto A., Hirata Y., Kakoki M., et al. Increased excretion of nitric oxide in exhaled air of patients with chronic renal failure. Clin Sci (Colch) 1999, 96:67-74.
38. Madore F., Prud'homme L., Austin J.S., et al. Impact of nitric oxide on blood pressure in hemodialysis patients. Am J Kidney 1997, Dis30:665-671.
39. Fernandez F., Goudrable C., Sie P., et al. Low haematocrit and prolonged bleeding time in uraemic patients: Effect of red cell transfusions. Br J Haematol 1985, 59:139-148.
40. Mannucci P.M., Remuzzi G., Pusinera F., et al. Desamino-8-d-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983, 308:8-12.
41. Mannucci P.M. Hemostatic drugs. N Engl J Med 1998, 339:245-253.
42. Janson P.A., Jubelirer J.J., Weinstein M.J., et al. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980, 303:1318-1322.
43. Liu Y., Kosfeld R.E., Marcum S.G. Treatment of uraemic bleeding with conjugated oestrogen. Lancet 1984, 2:887-890.
44. Livio M., Mannucci P.M., Vigano G., et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986, 315:731-735.
45. Sloand J.A., Schiff M.J. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia. Am J Kidney Dis 1995, 26:22-26.
46. Noris M., Todeschini M., Zappella S., et al. 17β-Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. Am J Physiol Renal Physiol 2000, 279:F626-F635.
47. Schafer A.I. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984, 64:1-12.
48. Wehmeier A., Sudhoff T., Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997, 23:391-402.
49. Ravandi-Kashani F., Schafer A.I. Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: Current concepts and perspectives. Semin Thromb Hemost 1997, 23:479-488.
50. Landolfi R., Marchioli R., Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997, 78:617-621.
51. Fenaux P., Simon M., Caulier M.T., et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990, 66:549-556.
52. Cortelazzo S., Viero P., Finazzi G., et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990, 8:556-562.
53. Johnson M., Gernsheimer T., Johansen K. Essential thrombocytosis: Underemphasized cause of largevessel thrombosis. J Vasc Surg 1995, 22:443-449.
54. van Genderen P.J., Michiels J.J. Erythromelalgia: A pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997, 23:357-363.
55. van Genderen P.J., Michiels J.J., van Strik R., et al. Platelet consumption in thrombocythemia complicated by erythromelalgia: Reversal by aspirin. Thromb Haemost 1995, 73:210-214.
56. Koudstaal P.J., Koudstaal A. Neurologic and visual symptoms in essential thrombocythemia: Effi-cacy of low-dose aspirin. Semin Thromb Hemost 1997, 23:365-370.
57. Tefferi A., Hoagland H.C. Issues in the diagnosis and management of essential thrombocythemia. Mayo Clinic Proc 1994, 69:651-655.
58. Colombi M., Radaelli F., Zocchi L., et al. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991, 67:2926-2930.
59. Lahuerta-Palacios J.J., Bornstein R., Fernandez-Debora F.J., et al. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 1988, 61:1207-1212.
60. Juvonen E., Ikkala E., Oksanen K., et al. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: Diagnostic value and correlation to complications. Br J Haematol 1993, 83:192-197.
61. Watson K.V., Key N. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors. Br J Haematol 1993, 83:198-203.
62. Besses C., Cervantes F., Pereira A., et al. Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients. Leukemia 1999, 13:150-154.
63. Wehmeier A., Daum I., Jamin H., et al. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991, 63:101-106.
64. Pearson T.C. Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Semin Thromb Hemost 1997, 23:433-439.
65. Rinder H.M., Schuster J.E., Rinder C.S., et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998, 91:1288-1294.
66. De Stefano V., Teofili L., Leone G., et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997, 23:411-418.
67. Rozman C., Giralt M., Feliu E., et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991, 67:2658-2663.
68. Berk P.D., Wasswerman L.R., Fruchtman S.M., et al. Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group. Polycythemia vera and the myeloproliferative disorders 1995, 166-194. Saunders, Philadelphia. L.R. Wasserman, P.D. Berk, N.I. Berlin (Eds.).
69. Gruppo Italiano Studio Policitemia Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 1995, 123:654-656.
70. Rao A.K. Acquired qualitative platelet defects. Hemostasis and thrombosis: Basic principles and clinical practice 2001, 905-920. Lippincott, Philadelphia. 4th ed. R.W. Colman, J. Hirsh, V.J. Marder (Eds.).
71. Small B.M., Bettigole R.E. Diagnosis of myeloproliferative disease by analysis of the platelet volume distribution. Am J Clin Pathol 1981, 76:685-691.
72. Van der Lelie J., Von dem Borne A.K. Platelet volume analysis for differential diagnosis of thrombocytosis. J Clin Pathol 1986, 39:129-133.
73. Maldonado J.E., Pintado T., Pierre R.V. Dysplastic platelet and circulating megakaryocytes in chronic myeloproliferative diseases. I. The platelets: Ultrastructure and peroxidase reaction. Blood 1974, 43:797-809.
74. Swart S.S., Pearson D., Wood J.K., et al. Functional significance of the platelet α2-adrenoceptor: Studies in patients with myeloproliferative disorders. Thromb Res 1984, 33:531-541.
75. Rendu F., Lebret M., Nurden A., et al. Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder. Thromb Haemostas 1979, 42:794-796.
76. Caranobe C., Sie P., Nouvel C., et al. Platelets in myeloproliferative disorders. II. Serotonin uptake and storage: Correlation with mepacrine labelled dense bodies and with platelet density. Scand J Haematol 1980, 25:289-295.
77. Malpass T.W., Savage B., Hanson S.R., et al. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med 1984, 103:894-904.
78. Holme S., Murphy S. Studies of the platelet density abnormality in myeloproliferative disease. J Lab Clin Med 1984, 103:373-383.
79. Murphy S., Davis J.L., Walsh P.N., et al. Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch Intern Med 1978, 138:1251-1253.
80. Boneu B., Nouvel C., Sie P., et al. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests. Scand J Haematol 1980, 25:214-220.
81. Balduini C.L., Bertolino G., Noris P., et al. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991, 95:82-86.
82. Waddell C.C., Brown J.A., Repinecz Y.A. Abnormal platelet function in myeloproliferative disorders. Arch Path Lab Med 1981, 105:432-435.
83. Wu K.K. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 1978, 88:7-11.
84. Kaywin P., McDonough M., Insel P.A., et al. Platelet function in essential thrombocythemia: Decreased ephinephrine responsiveness associated to α adrenergic receptors. N Engl J Med 1978, 299:505-509.
85. Pfeifer M.A., Ward K., Malpass T., et al. Variations in circulating catecholamines fail to alter human platelet α-2-adrenergic receptor number or affinity for [3H]yohimbine or [3H]dihydroergocryptine. J Clin Invest 1984, 74:1063-1072.
86. Swart S.S., Wood J.K., Barnett D.B. Differential labeling of platelet α 2 adrenoceptors by 3H dihydroergocryptine and 3H yohimbine in patients with myeloproliferative disorders. Thromb Res 1985, 40:623-629.
87. Swart S.S., Maguire M., Wood J.K., et al. α 2-adrenoceptor coupling to adenylate cyclase in adrenaline insensitive human platelets. Eur J Pharmacol 1985, 116:113-119.
88. Ushikubi F., Okuma M., Ishibashi T., et al. Deficient elevation of the cytoplasmic calcium ion concentration by epinephrine in epinephrine-insensitive platelets of patients with myeloproliferative disorders. Am J Hematol 1990, 33:96-100.
89. Gugliotta L., Pickering C., Greaves M., et al. Abnormality of platelet membrane glycoproteins in essential thrombocythemia. Thromb Haemostas 1983, 50:216.
90. Mazzucato M., De Marco L., De Angelis V., et al. Platelet membrane abnormalities in myeloproliferative disorders: Decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 1989, 73:369-374.
91. Eche N., Sie P., Caranobe C., et al. Platelets in myeloproliferative disorders. III: Glycoprotein profile in relation to platelet function and platelet density. Scand J Haematol 1981, 26:123-129.
92. Clezardin P., McGregor J.L., Dechavanne M., et al. Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. Br J Haematol 1985, 60:331-344.
93. Kaplan R., Gabbeta J., Sun L., et al. Combined defect in membrane expression and activation of platelet GPIIb-IIIa complex without primary sequence abnormalities in myeloproliferative disease. Br J Haematol 2000, 111:954-964.
94. Landolfi R. Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol 1998, 5:327-331.
95. Mistry R., Cahill M., Chapman C., et al. 125I-fibrinogen binding to platelets in myeloproliferative disease. Thromb Haemost 1991, 66:329-333.
96. Handa M., Watanabe K., Kawai Y., et al. Platelet unresponsiveness to collagen: Involvement of glycoprotein Ia-IIa (α 2b 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost 1995, 73:521-528.
97. Legrand C., Bellucci S., Disdier M., et al. Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia: Effect of α-interferon treatment. Am J Hematol 1991, 38:307-313.
98. Thibert V., Bellucci S., Cristofari M., et al. Increased platelet CD36 constitutes a common marker in myeloproliferative disorders. Br J Haematol 1995, 91:618-624.
99. Bolin R.B., Okumura T., Jamieson G.A. Changes in the distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders. Am J Hematol 1977, 3:63-71.
100. Wehmeier A., Tschope D., Esser J., et al. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991, 61:271-278.
101. Moore A., Nachman R.L. Platelet Fc receptor: Increased expression in myeloproliferative disease. J Clin Invest 1981, 67:1064-1071.
102. Okuma M., Hirata T., Ushikubi F., et al. Molecular characterization of a dominantly inherited bleeding disorder with impaired platelet responses to thromboxane A2. Pol J Pharmacol 1996, 48:77-82.
103. Russel N.H., Salmon J., Keenan J.P., et al. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res 1981, 22:389-397.
104. Schafer A.I. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 1982, 306:381-386.
105. van Genderen P.J., Michiels J.J., Zijlstra F.J. Lipoxygenase deficiency in primary thrombocythemia is not a true deficiency. Thromb Haemost 1994, 71:803-804.
106. Smith I.L., Martin T.J. Platelet thromboxane synthesis and release reactions in myeloproliferative disorders. Haemostasis 1982, 11:119-127.
107. Zahavi J., Zahavi M., Firsteter E., et al. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 1991, 47:326-332.
108. Rocca B., Ciabattoni G., Tartaglione R., et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995, 74:1225-1230.
109. Takayama H., Okuma M., Kanaji K., et al. Altered arachidonate metabolism by leukocytes and platelets in myeloproliferative disorders. Prostaglandins Leukot Med 1983, 12:261-272.
110. Stenke L., Edenius C., Samuelsson J., et al. Deficient lipoxin synthesis: A novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 1991, 78:2989-2995.
111. Fujimoto T., Fujimura K., Kuramoto A. Abnormal Ca2+ homeostasis in platelets with myeloproliferative disorders: Low levels of Ca2+ influx and efflux across the plasma membrane and increased Ca2+ accumulation into the dense tubular system. Thromb Res 1989, 53:99-108.
112. Ushikubi F., Ishibashi T., Narumiya S., et al. Analysis of the defective signal transduction mechanism through the platelet thromboxane A2 receptor in a patient with polycythemia vera. Thromb Hemostas 1992, 67:144-146.
113. Eigenthaler M., Ullrich H., Geiger J., et al. Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinasedefi cient human platelets of chronic myelocytic leukemia. J Biol Chem 1993, 268:13526-13531.
114. Cooper B., Schafer A.I., Puchalsky D., et al. Platelet resistance to protaglandin D2 in patients with myeloproliferative disorders. Blood 1978, 52:618-626.
115. Cortelazzo S., Galli M., Castagna D., et al. Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disorders. Thromb Haemost 1988, 59:73-76.
116. Moliterno A.R., Siebel K.E., Sun A.Y., et al. A novel thrombopoietin signaling defect in polycythemia vera platelets. Stem Cells 1998, 16:185-192.
117. Best D., Pasquet S., Littlewood T.J., et al. Platelet activation via the collagen receptor GPVI is not altered in platelets from chronic myeloid leukaemia patients despite the presence of the constitutively phosphorylated adapter protein CrkL. Br J Haematol 2001, 112:609-615.
118. Budde U., van Genderen P.J. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997, 23:425-431.
119. Tefferi A., Gilliland D.G. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implications for disease classification and diagnosis. Mayo Clinic Proc 2005, 80:947-958.
120. Cowan D.H., Graham R.C. Structural-functional relationships in platelets in acute leukemia and related disorders. Series Haematologica 1975, 8:68.
121. Cowan D.H., Graham R.C., Baunach D. The platelet defect in leukemia, platelet ultrastructure, adenine nucleotide metabolism and the release reaction. J Clin Invest 1975, 56:188.
122. Stuart J.J., Lewis J.C. Platelet aggregation and electron microscopic studies of platelets in preleukemia. Arch Path Lab Med 1982, 106:458.
123. Levine P.H., Katayama I. The platelet in leukemic reticuloendotheliosis. Functional and morphological evidence of a qualitative disorder. Cancer 1975, 36:1353.
124. Nouvel C., Caronobe C., Sie P., et al. Platelet volume, density and 5HT organelles (Mepacrine test) in acute leukemia. Scand J Haematol 1978, 21:421.
125. Russell N.H., Keenan J.P., Bellingham A.J. Platelet adenine nucleotides and arachidonic acid metabolism in myeloproliferative diseases. Thromb Res 1981, 22:389.
126. Maldonado J.E., Pierre sR.V. The platelets in preleukemia and myelomonocytic leukemia. Ultrastructural cytochemistry and cytogenetics. Mayo Clinic Proc 1975, 50:573.
127. Sweet D.L., Golomb H.M. Correction of platelet defect after splenectomy in hairy cell leukemia. J Am Med Assoc 1979, 241:1684.
128. Rosove M.H., Naeim F., Harwig S., et al. Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy. Blood 1980, 55:903-906.
129. Zuzel M., Cawley J.C., Paton R.C., et al. Platelet function in hairy-cell leukaemia. J Clin Pathol 1979, 32:814-821.
130. Roussi J.H., Houbouyan L.L., Alterscu R., et al. Acquired von Willebrand's syndrome associated with hairy cell leukemia. Br J Haematol 1980, 46:503-506.
131. Berndt M.C., Kabral A., Grimsley P., et al. An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 1988, 68:97-101.
132. Robert F., Mignucci M., McCurdy S.A., et al. Hemostatic abnormalities associated with monoclonal gammopathies. Am J Med Sci 1993, 306:359-366.
133. Furie B., Greene E., Furie B.C. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977, 297:81-85.
134. Palmer R.N., Rick M.E., Rick P.D., et al. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med 1984, 310:1696-1699.
135. Lackner H. Hemostatic abnormalities associated with dysproteinemias. Semin Hematol 1973, 10:125-133.
136. DiMinno G., Coraggio F., Cerbone A.M., et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986, 77:157-164.
137. Mohri H., Noguchi T., Kodoma F., et al. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Pathol 1987, 97:663-668.
138. Vigliano E.M., Horowitz H.I. Bleeding syndrome in a patient with IgA myeloma: Interaction of protein and connective tissue. Blood 1967, 29:823-836.
139. Bovill E.G., Ershler W.B., Golden E.A., et al. A human myeloma produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 1986, 85:115-123.
140. Bovill E.G., Ershler W.B., Golden E.A., et al. DDAVP in acquired von Willebrand syndrome associated with multiple myeloma. Am J Hematol 1986, 122:421-423.
141. Kumar S., Pruthi R.K., Nichols W.L. Acquired von Willebrand disease. Mayo Clinic Proc 2002, 77:181-187.
142. Federici A.B., Rand J.H., Bucciarelli P., et al. Acquired von Willebrand syndrome: Data from an international registry. Thromb Haemost 2000, 84:345-349.
143. Budde U., Scharf R.E., Franke P., et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993, 82:1749-1757.
144. van Genderen P.J., Budde U., Michiels J.J., et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996, 93:962-965.
145. Castaman G., Lattuada A., Mannucci P.M., et al. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin: Evidence for heightened proteolysis of von Willebrand factor. Am J Hematol 1995, 49:83-86.
146. Kreuz W., Linde R., Funk M., et al. Induction of von Willebrand disease type I by valproic acid. Lancet 1990, 335:1350-1351.
147. Conrad M.E., Latour L.F. Acquired von Willebrand's disease, IgE polyclonal gammopathy and griseofulvin therapy. Am J Hematol 1992, 41:143.
148. Lazarchick J., Conroy J.M. The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: Ristocetin cofactor activity. Ann Clin Lab Sci 1995, 25:306-309.
149. Dalrymple-Hay M., Aitchison R., Collins P., et al. Hydroxyethyl starch induced acquired von Willebrand's disease. Clin Lab Haematol 1992, 14:209-211.
150. Jonge Poerink-Stockschlader A.B., Dekker I., Risseeuw-Appel I.M., et al. Acquired Von Willebrand disease in children with a Wilms' tumor. Med Pediatr Oncol 1996, 26:238-243.
151. Gill J.C., Wilson A.D., Endres-Brooks J., et al. Loss of the largest von Willebrand factor multimers from plasma of patients with congenital cardiac defects. Blood 1986, 67:758-761.
152. Vincentelli A., Susen S., Le Tourneau T., et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003, 349:343-349.
153. Mohri H., Motomura S., Kanamori H., et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998, 91:3623-3629.
154. Sadler J.E. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003, 349:323-325.
155. Levesque H., Borg J.Y., Cailleux N., et al. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism. Eur J Med 1993, 2:287-288.
156. Friederich P.W., Wever P.C., Briet E., et al. Successful treatment with recombinant factor VIIa of therapyresistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001, 66:292-294.
157. Federici A.B., Stabile F., Castaman G., et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches. Blood 1998, 92:2707-2711.
158. Agarwal N., Klix M.M., Burns C.P. Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. Ann Intern Med 2004, 141:83-84.
159. Bovill E.G., Ershler W.B., Golden E.A., et al. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 1986, 85:115-123.
160. Uehlinger J., Button G.R., McCarthy J., et al. Immunoadsorption for coagulation factor inhibitors. Transfusion 1991, 31:265-269.
161. Budde U., Schaefer G., Mueller N., et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984, 64:981-985.
162. Budde U., Dent J.A., Berkowitz S.D., et al. Subunit composition of plasma von Willebrand factor in patients with myeloproliferative syndrome. Blood 1986, 68:1213-1217.
163. van Genderen P.J., Prins F.J., Lucas I.S., et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: Normalization after cytoreduction of the increased platelet count. Br J Haematol 1997, 99:832-836.
164. Zahavi J., Marder V.J. Acquired storage pool disease of platelets associated with circulating anti-platelet antibodies. Am J Med 1974, 56:883-889.
165. Weiss H.J., Rosove M.H., Lages B.A., et al. Acquired storage pool deficiency with increased plateletassociated IgG. Report of five cases. Am J Med 1980, 69:711-717.
166. Rendu F., Lebret M., Nurden A., et al. Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder. Thromb Haemost 1979, 42:794.
167. Russel N.H., Salmon J., Keenan J.P., et al. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res 1981, 22:389.
168. Cowan D.H., Graham R.C., Baunach D. The platelet defect in leukemia, platelet ultrastructure, adenine nucleotide metabolism and the release reaction. J Clin Invest 1975, 56:188.
169. Pareti F.I., Gugliotta L., Mannucci L., et al. Biochemical and metabolic aspects of platelet dysfunction in myeloproliferative disorders. Thromb Haemost 1982, 47:84.
170. Pareti F.I., Capitanio A., Mannucci P.M. Acquired storage pool disease in platelets during disseminated intravascular coagulation. Blood 1976, 48:511.
171. Pareti F.I., Capitanio A., Mannucci C., et al. Acquired dysfunction due to circulation of "exhausted" platelets. Am J Med 1980, 69:235.
172. Khurana M.S., Lian E.C.Y., Harkness D.R. Storage pool disease of platelets associated with multiple congenital cavernous hemangiomas. J Am Med Assoc 1980, 244:169.
173. Nenci G.G., Gresele P., Agnetti F., et al. Intrinsically defective or exhausted platelets in hairy cell leukemia?. Thromb Haemost 1981, 46:572.
174. Harker L.A., Malpass T.W., Branson H.E., et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective α granule release. Blood 1980, 55:824-834.
175. Beurling-Harbury C., Galvan C.A. Acquired decreased in platelet secretory ADP associated with increased postoperative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. Blood 1978, 52:13-23.
176. Savage B., Malpass T.W., Stratton J.R., et al. Platelet adenine nucleotide levels in patients with Dacron vascular prostheses. Thromb Res 1983, 32:365-372.
177. Rao A.K., Niewiarowski S., Murphy S. Acquired granular pool defect in stored platelets. Blood 1981, 57:203-208.
178. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and puri-fied ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102:887-895.
179. Takahashi R., Sekine N., Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999, 93:1951-1958.
180. Harker L.A., Slichter S.J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972, 287:155-159.
181. Clancy R., Jenkins E., Firkin B. Qualitative platelet abnormalities in idiopathic thrombocytopenic purpura. N Engl J Med 1972, 286:622-626.
182. Zahavi J., Marder V.J. Acquired storage pool disease of platelets associated with circulating anti-platelet antibodies. Am J Med 1974, 56:883.
183. Weiss H.J., Rosove M.H., Lages B.A., et al. Acquired storage pool deficiency with increased plateletassociated IgG. Report of five cases. Am J Med 1980, 69:711.
184. Karpatkin S., Lackner H.L. Association of antiplatelet antibody with functional platelet disorders: Autoimmune thrombocytopenic purpura, systemic lupus erythematosus and thrombopathia. Am J Med 1975, 59:599-604.
185. Lackner H.L., Karpatkin S. On the "easy bruising" syndrome with normal platelet count. A study of 75 patients. Ann Intern Med 1975, 83:190.
186. Heyns A., Fraser J., Retief sF.P. Platelet aggregation in chronic idiopathic thrombocytopenic purpura. J Clin Pathol 1978, 31:1239.
187. Stuart M.J., Kelton J.G., Allen J.B. Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura. Blood 1981, 58:326.
188. Regan M.G., Lackner H.L., Karpatkin S. Platelet function and coagulation profile in lupus erythematosus. Ann Intern Med 1974, 81:462.
189. Dorsch C.A., Meyerhoff J. Mechanisms of abnormal platelet aggregation in systemic lupus erythematosus. Arthritis Rheum 1982, 25:966.
190. Kurata Y., Nishioeda Y., Tusubakio T., et al. Thrombocytopenia in Graves' disease: Effect of T3 on platelet kinetics. Acta Haematol 1980, 63:185.
191. Woods V.L., Kurata Y., Montgomery R.R., et al. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 1984, 64:156-160.
192. Szatkowski N.S., Kunicki T.J., Aster R.H. Identification of glycoprotein Ib as a target for autoantibody in idiopathic (autoimmune) thrombocytopenic purpura. Blood 1986, 67:310-315.
193. Woods V.L., Oh E.H., Mason D., et al. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood 1984, 63:368-375.
194. Berchtold P., McMillan R., Tani P., et al. Autoantibodies against platelet membrane glycoproteins in children with acute and chronic immune thrombocytopenic purpura. Blood 1989, 74:1600-1602.
195. Deckmyn H., Zhang J., Van Houtte E., et al. Production and nucleotide sequence of an inhibitory human IgM autoantibody directed against platelet glycoprotein Ia/ IIa. Blood 1994, 84:1968-1974.
196. Dromigny A., Triadou P., Lesavre P., et al. Lack of platelet response to collagen associated with autoantibodies against glycoprotein (GP) Ia/IIa and Ib/IX leading to the discovery of SLE. Hematol Cell Ther 1996, 38:355-357.
197. Rao A.K., Kowalska M.A., Karczewski J., et al. Impaired platelet response to collagen and human antibody against an 88-kilodalton platelet membrane glycoprotein. Thromb Haemost 1989, 62:506.
198. Sugiyama T., Okuma M., Ushikubi F., et al. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 1987, 69:1712-1720.
199. Boylan B., Chen H., Rathore V., et al. Anti-GPVIassociated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgammachain complex from the human platelet surface. Blood 2004, 104:1350-1355.
200. van Vliet H.H., Kappers-Klunne M.C., van der Hel J.W., et al. Antibodies against glycosphingolipids in sera of patients with idiopathic thrombocytopenic purpura. Br J Haematol 1987, 67:103-108.
201. Koerner T.A., Weinfeld H.M., Bullard L.S., et al. Antibodies against platelet glycosphingolipids: Detection in serum by quantitative HPTLC-autoradiography and asso-ciation with autoimmune and alloimmune processes. Blood 1989, 74:274-284.
202. Sugiyama T., Okuma M., Ushikubi F., et al. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 1987, 69:1712-1720.
203. McMillan R., Tani P., Millard F., et al. Plateletassociated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood 1987, 70:1040-1045.
204. Kiefel V., Santoso S., Kaufmann E., et al. Autoantibodies against platelet glycoprotein Ib/IX: A frequent finding in autoimmune thrombocytopenic purpura. Br J Haematol 1991, 79:256-262.
205. Kiefel V., Freitag E., Kroll H., et al. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol 1996, 72:280-285.
206. Stuart M.J., Kelton J.G., Allen J.B. Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura. Blood 1981, 58:326-329.
207. Meyerhoff J., Dorsch C.A. Decreased platelet serotonin levels in systemic lupus erythematosus. Arthritis Rheum 1981, 24:1495-1500.
208. Thomas D.P., Ream V.J., Stuart R.K. Platelet aggregation in patients with Laennec's cirrhosis of the liver. N Engl J Med 1967, 276:1344-1348.
209. Thomas D.P. Abnormalities of platelet aggregation in patients with alcoholic cirrhosis. Ann N Y Acad Sci 1967, 201:243.
210. Ballard H.S., Marcus A.J. Platelet aggregation in portal cirrhosis. Arch Intern Med 1976, 136:316-319.
211. Ingeberg S., Jacobsen P., Fisher E., et al. Platelet aggregation and release of ATP in patients with hepatic cirrhosis. Scand J Gastroenterol 1985, 20:285-288.
212. Laffi G., Cominelli F., Ruggiero M., et al. Molecular mechanism underlying platelet responsiveness in liver cirrhosis. Fed Eur Biochem Soc 1987, 220:217-219.
213. Hillbom M., Muuronen A., Neiman J. Liver disease and platelet function in alcoholics. Br Med J (Clin Res Ed) 1987, 295:581.
214. Stein S.F., Harker L.A. Kinetic and functional studies of platelets, fibrinogen and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982, 99:217-230.
215. Laffi G., Cominelli F., Ruggiero M., et al. Altered platelet function in cirrhosis of the liver: Impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988, 8:1620-1626.
216. Desai K., Mistry P., Bagget C., et al. Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis. Lancet 1989, 1:693-695.
217. Cowan D.H. Effect of alcoholism on hemostasis. Semin Hematol 1980, 17:137-147.
218. Hillbom M., Neiman J. Platelet thromboxane formation capacity after ethanol withdrawal in chronic alcoholics. Haemostasis 1988, 18:170-178.
219. Mannucci P.M., Vicente V., Vianello L., et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986, 67:1148-1153.
220. Lopez P., Otaso J.C., Alvarez D., et al. Hemostatic and hemodynamic effects of vasopressin analogue DDAVP in patients with cirrhosis. Acta Gastroenterol Latinoam 1997, 27:59-62.
221. Cattaneo M., Tenconi P.M., Alberca I., et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990, 64:358-360.
222. Ingeberg S., Stoffersen E. Platelet dysfunction in patients with vitamin B12 deficiency. Acta Haematol 1979, 61:75-79.
223. Laosombat V., Wongchanchailert M., Sattayasevana B., et al. Acquired platelet dysfunction with eosinophilia in children in the south of Thailand. Platelets 2001, 12:5-14.
224. Lim S.H., Tan C.E., Agasthian T., et al. Acquired platelet dysfunction with eosinophilia: Review of seven adult cases. J Clin Pathol 1989, 42:950-952.
225. Poon M.C., Ng S.C., Coppes M.J. Acquired platelet dysfunction with eosinophilia in white children. J Pediatr 1995, 126:959-961.
226. Solinger A., Bernstein I.L., Glueck H.I. The effect of epinephrine on platelet aggregation in normal and atopic patients. J Allergy Clin Immunol 1973, 51:29-34.
227. Szczeklik A., Milner P.C., Birch J., et al. Prolonged bleeding time, reduced platelet aggregation, altered PAF-acether sensitivity and increased platelet mass are a trait of asthma and hay fever. Thromb Haemost 1986, 56:283-287.
228. Stoff J.S., Stomerman M., Steer M., et al. A defect in platelet aggregation in Bartter's syndrome. Am J Med 1980, 68:171-180.
229. Smith J.B., Willis A.L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971, 231:235-237.
230. Roth G.J., Majerus P.W. The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particular fraction protein. J Clin Invest 1975, 56:624-632.
231. Pedersen A.K., Fitzgerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984, 311:1206-1211.
232. Patrigrani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982, 69:1366-1372.
233. Weksler B.B., Pett S.B., Alonso D., et al. Differential inhibition of aspirin of vascular prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983, 308:800-805.
234. Antiplatelet Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002, 324:71-86.
235. Patrono C., Coller B., Fitzgerald G.A., et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:234S-264S.
236. O'Grady J., Moncada S. Aspirin: A paradoxical effect on bleeding time. Lancet 1978, 2:780.
237. Rajah S.M., Penny S.M., Kester R. Aspirin and bleeding time. Lancet 1978, 2:1104.
238. Mielke C.H. Aspirin prolongation of the template bleeding time: Influence of venostasis and direction of incision. Blood 1982, 60:1139-1142.
239. Hayward C.P., Harrison P., Cattaneo M., et al. The closure times in the evaluation of platelet disorders and function: A report from the Working Group on the PFA-100,, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2006, 4:312-319.
240. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,, 036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005, 95:1218-1222.
241. Rumack C.M., Guggenheim M.A., Rumack B.H., et al. Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol 1981, 58:52S-56S.
242. Bleyer W.A., Breckenridge R.T. Studies on the detection of adverse drug reactions in the newborn: II. The effects of prenatal aspirin on newborn hemostasis. J Am Med Assoc 1970, 213:2049-2053.
243. Stuart M.J., Gross S.J., Elrad H., et al. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med 1982, 307:909-912.
244. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321:129-135.
245. Merritt J.C., Bhatt D.L. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis 2002, 13:97-103.
246. Sethi G.K., Copeland J.G., Goldman S., et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 1990, 15:15-20.
247. Mangano D.T. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002, 347:1309-1317.
248. Roderick P.J., Wilkes H.C., Meade T.W. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials. Br J Clin Pharmacol 1993, 35:219-226.
249. Diener H.C., Cunha L., Forbes C., et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
250. The Dutch TIA Trial Study Group A comparison of two doses of aspirin (30 mg vs 823 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991, 325:1261-1266.
251. Garcia Rodriguez L.A., Cattaruzzi C., Troncon M.G., et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998, 158:33-39.
252. Henry D., Lim L.L., Garcia Rodriguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br Med J 1996, 312:1563-1566.
253. Stein P.D., Dalen J.E., Goldman S., et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 2001, 119:278S-282S.
254. Topol E.J. Aspirin with bypass surgery -From taboo to new standard of care. N Engl J Med 2002, 347:1359-1360.
255. Mannucci P.M. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997, 90:2515-2521.
256. Simon L.S., Mills J.A. Drug therapy: Nonsteroidal antiinflammatory drugs (first of two parts). N Engl J Med 1980, 302:1179-1185.
257. Zucker M.B., Peterson J. Effect of acetylsalicyclic acid, other nonsteroidal anti-inflammatory agents and dipyridamole on human blood platelets. J Lab Clin Med 1970, 76:66-75.
258. O'Brien J.R., Finch W., Clark E. A comparison of an effect of different anti-inflammatory drugs on human platelets. J Clin Pathol 1970, 23:522-525.
259. O'Brien J.R. Effect of anti-inflammatory agents on platelets. Lancet 1968, 1:894-895.
260. Ali M., McDonald J.W.D. Reversible and irreversible inhibition of platelet cyclooxygenase and serotonin release by nonsteroidal anti-inflammatory drugs. Thromb Res 1978, 13:1057.
261. Nishizawa E.E., Wynalda D.J. Inhibitory effect of ibuprofen (Motrin) on platelet function. Thromb Res 1981, 21:347-356.
262. Green D., Given K.M., Ts'ao C.H., et al. The effect of a new non-steroidal anti-inflammatory agent, sulindac, on platelet function. Thromb Res 1977, 10:283-289.
263. Ali M., McDonald J.W.D. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J Lab Clin Med 1977, 89:868-875.
264. Cerskus A.L., Ali M., McDonald J.W.D. Thromboxane B2 and 6-keto-prostaglandin F1 synthesis during infusion of collagen and arachidonic acid in rabbits: Inhibition by aspirin and sulfinpyrazone. Thromb Res 1980, 18:693-705.
265. Simon L.S., Mills J.A. Nonsteroidal antiin-flammatory drugs (second of two parts). N Engl J Med 1980, 302:1237-1243.
266. McQueen E.G., Facoory B. Nonsteroidal antiinfl ammatory drugs and platelet function. N Z Med J 1986, 99:358-360.
267. Thomas P., Hepburn B., Kim H.C., et al. Nonsteroidal anti-inflammatory drugs in the treatment of hemophilic arthropathy. Am J Hematol 1982, 12:131-137.
268. Ragni M.V., Miller B.J., Whalen R., et al. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV (+) hemophilic men. Am J Hematol 1992, 40:176-182.
269. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
270. Feldman M., McMahon A.T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?. Ann Intern Med 2000, 132:134-143.
271. Lages B., Weiss H.J. Inhibition of human platelet function in vitro and ex vivo by acetaminophen. Thromb Res 1989, 53:603-613.
272. Sharis P.J., Cannon C.P., Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998, 129:394-405.
273. Coukell A.J., Markham A. Clopidogrel. Drugs 1997, 54:745-750.
274. Mills D.C., Puri R., Hu C.J., et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992, 12:430-436.
275. Wilhite D.B., Comerota A.J., Schmieder F.A., et al. Managing PAD with multiple platelet inhibitors: The effect of combination therapy on bleeding time. J Vasc Surg 2003, 38:710-713.
276. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998, 128:541-544.
277. Bennett C., Kiss J., Weinberg P., et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998, 352:1036-1037.
278. Bennett C.L., Connors J.M., Carwile J.M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000, 342:1773-1777.
279. Aster R.H., Curtis B.R., Bougie D.W. Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. Semin Thromb Hemost 2004, 30:569-577.
280. Szczeklik A., Gryglewski R.J., Nizankowski R., et al. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun 1978, 10:545-556.
281. Fitzgerald G.A., Friedman L.A., Miyamori I., et al. A double blind placebo controlled crossover study of prostacylin in man. Life Sci 1979, 25:665-672.
282. Fitzgerald G.A. Dipyridamole. N Engl J Med 1987, 316:1247-1257.
283. Kim J.S., Lee K.S., Kim Y.I., et al. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: Analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004, 11:600-602.
284. Dawson D.L., Cutler B.S., Meissner M.H., et al. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998, 98:678-686.
285. Ardlie N.G., Glew G., Schultz B.G., et al. Inhibition and reversal of platelet aggregation by methylxanthines. Thrombos Diath Haemorrh 1968, 18:670.
286. Wallis R.M., Corbin J.D., Francis S.H., et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999, 83:3C-12C.
287. Halcox J.P., Nour K.R., Zalos G., et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002, 40:1232-1240.
288. Cheung P.Y., Salas E., Schulz R., et al. Nitric oxide and platelet function: Implications for neonatology. Semin Perinatol 1997, 21:409-417.
289. Freedman J.E., Loscalzo J., Barnard M.R., et al. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997, 100:350-356.
290. Samama C.M., Diaby M., Fellahi J.L., et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1995, 83:56-65.
291. Brown C.H., Natelson E.A., Bradshaw M.W., et al. The hemostatic defect produced by carbenicillin. N Engl J Med 1974, 291:265-270.
292. Haburchak D.R., Head D.R., Everett E.D. Postoperative hemorrhage associated with carbenicillin administration -Report of two cases and review of the literature. Am J Surg 1977, 134:630-634.
293. Brown C.H., Bradshaw M.W., Natelson E.A., et al. Defective platelet function following the administration of penicillin compounds. Blood 1976, 47:949-956.
294. Andrassy K., Ritz E., Hasper B., et al. Penicillininduced coagulation disorder. Lancet 1976, 2:1039-1041.
295. Cazenave J.P., Guccione M.A., Packham M.A., et al. Effects of cephalothin and penicillin G on platelet function in vitro. Br J Haematol 1977, 35:135-152.
296. Fass R.J., Copelan E.A., Brandt J.T., et al. Platelet mediated bleeding caused by broad spectrum penicillins. J Infect Dis 1987, 155:1242-1248.
297. Brown C.H., Natelson E.A., Bradshaw M.W. A study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother 1975, 7:652-657.
298. Pillgram-Larsen J., Wisloff F., Jorgensen J.J., et al. Effect of high-dose ampicillin and cloxacillin on bleeding time and bleeding in open-heart surgery. Scand J Thorac Cardiovasc Surg 1985, 19:45-48.
299. Alexander D.P., Russo M.E., Fohrman D.E., et al. Nafcillin induced platelet dysfunction and bleeding. Antimicrob Agents Chemother 1983, 23:59-62.
300. Sattler F.R., Weitekamp M.R., Ballard J.O. Potential for bleeding with the new β-lactam antibiotics. Ann Intern Med 1986, 105:924-931.
301. Johnson G.J. Platelets, penicillins, and purpura: What does it all mean?. J Lab Clin Med 1993, 121:531-533.
302. Natelson E.A., Brown C.H., Bradshaw M.W., et al. Influence of cephalosporin antibiotics on blood coagulation and platelet function. Antimicrob Agents Chemother 1976, 9:91-93.
303. Weitekamp M.R., Aber R.C. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. J Am Med Assoc 1983, 249:69-71.
304. Sloand E.M., Klein H.G., Pastakia K.B., et al. Effect of albumin on the inhibition of platelet aggregation by β-lactam antibiotics. Blood 1992, 79:2022-2027.
305. Shattil S.J., Bennett J.S., McDonaugh M., et al. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest 1980, 65:329-337.
306. Burroughs S.F., Johnson G.J. β-Lactam antibiotic-induced platelet dysfunction: Evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin. Blood 1990, 75:1473-1480.
307. Burroughs S.F., Johnson G.J. β-Lactam antibiotics inhibit agonist-stimulated platelet calcium influx. Thromb Haemost 1993, 69:503-508.
308. Pastakia K.B., Terle D., Prodouz K.N. Penicillin-induced dysfunction of platelet membrane glycoproteins. J Lab Clin Med 1993, 121:546-554.
309. Rossi E.C., Levin N.W. Inhibition of primary ADP-induced platelet aggregation in normal subjects after administration of nitrofurtoin (Furadantin). J Clin Invest 1973, 52:2457-2467.
310. Cummins D., Faint R., Yardumian D.A., et al. The in-vitro and ex-vivo effects of chloroquine sulphate on platelet function: Implications for malaria prophylaxis in patients with impaired haemostasis. J Trop Med Hyg 1990, 93:112-115.
311. Ishikawa S., Manabe S., Wada O. Miconazole inhibition of platelet aggregation by inhibiting cyclooxygenase. Biochem Pharmacol 1986, 35:1787-1792.
312. Weksler B.B., Gillik M., Pink J. Effect of propranolol on platelet function. Blood 1977, 49:185-196.
313. Petrikova M., Jancinova V., Nosal R., et al. Antiplatelet activity of carvedilol in comparison to propranolol. Platelets 2002, 13:479-485.
314. Dash D., Rao K. Effect of propranolol on platelet signal transduction. Biochem J 1995, 309:99-104. (Pt 1).
315. Leon R., Tiarks C.Y., Pechet L. Some observations on the in vivo effect of propranolol on platelet aggregation and release. Am J Hematol 1978, 5:117-121.
316. Frishman W.H., Weksler B., Christodoulo J.B., et al. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris. Circulation 1974, 50:887-896.
317. Vanderhoek J.Y., Feinstein M.B. Local anesthetics, chlorpromazine and propranolol inhibit stimulusactivation of phospholipase A2 in human platelets. Mol Pharmacol 1979, 16:171-180.
318. Mehta J., Mehta P. Effects of propranolol therapy on platelet release and prostaglandin generation in patients with coronary heart disease. Circulation 1982, 66:1294-1299.
319. Srivastava K.C. Influence of some β blockers (pindolol, atenolol, timolol and metoprolol) on aggregation and arachidonic acid metabolism in human platelets. Prostaglandins Leukot Med 1987, 29:79-84.
320. Ingerman C.M., Smith J.B., Silver M.J. Inhibition of the platelet release reaction and platelet prostaglandin synthesis by furosemide. Thromb Res 1976, 8:417-419.
321. Pfister B., Imhof P. Influence of vasodilators used in the therapy of heart failure on platelet aggregation. Agents Actions 1979, 9:217-219.
322. Saxon A., Kattlove H. Platelet inhibition by sodium nitroprusside, a smooth muscle inhibitor. Blood 1976, 47:957-961.
323. Mehta J., Mehta P. Platelet function in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure. Inhibition by sodium nitroprusside. Circulation 1979, 60:497-503.
324. Hines R., Barash P.G. Infusion of sodium nitroprusside induces platelet dysfunction in vitro. Anesthesiology 1989, 70:611-615.
325. Schafer A.J., Alexander R.W., Handin R.I. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980, 55:649-654.
326. Lawson D., Mehta J., Mehta P., et al. Cumulative effects of quinidine and aspirin on bleeding time and platelet α2-adrenoreceptors: Potential mechanism of bleeding diathesis in patients receiving this combination. J Lab Clin Med 1986, 108:581-586.
327. Motulsky H.J., Maisel A.S., Snavely M.D., et al. Quinidine is a competitive antagonist at α1-and α2-adrenergic receptors. Circ Res 1984, 55:376-381.
328. Ring M.E., Corrigan J.J., Fenster P.E. Effects of oral diltiazem on platelet function: Alone and in combination with "low dose" aspirin. Thromb Res 1986, 44:391-400.
329. Ware J.A., Johnson P.C., Smith M., et al. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: Studies with aequorin and quin2. Circ Res 1986, 59:39-42.
330. Barnathan E.S., Addonizio V.P., Shattil S.J. Interaction of verapamil with human platelet α-adrenergic receptors. Am J Physiol 1982, 242:H19-H23.
331. Johnson G.J., Leis L.A., Francis G.S. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on α2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets. Circulation 1986, 73:847-854.
332. Glusa E., Bevan J., Heptinstall S. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. Thromb Res 1989, 55:239-245.
333. Ambrosioni E., Borghi C. Potential use of ACE inhibitors after acute myocardial infarction. J Cardiovasc Pharmacol 1989, 14:S92-S94.
334. James I.M., Dickenson E.J., Burgoyne W., et al. Treatment of hypertension with captopril: Preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens 1988, 2:21-25.
335. Okrucka A., Pechan J., Kratochvilova H. Effects of the angiotensin-converted enzyme inhibitor perindopril on endothelial and platelet function in essential hypertension. Platelets 1998, 9:395-396.
336. Keidar S., Oiknine J., Leiba A., et al. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. J Cardiovasc Pharmacol 1996, 27:183-186.
337. Moser L., Callahan K.S., Cheung A.K., et al. ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol 1997, 30:461-467.
338. Zannad F., Bray-Desboscs L., el Ghawi R., et al. Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: A randomly allocated double-blind study. J Hypertens 1993, 11:559-564.
339. Jagroop I.A., Papadaksi J.A., Mikhailidis D.P. Effects of the angiotensin-converting enzyme inhibitor perindopril on endotheial and platelet function in essential hypertension. Platelets 1998, 9:395-396.
340. Horne M.K.D., Chao E.S. Heparin binding to resting and activated platelets. Blood 1989, 74:238-243.
341. Salzman E.W., Rosenberg R.D., Smith M.H., et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980, 65:64-73.
342. Heiden D., Mielke C.H., Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol 1977, 36:427-436.
343. Sobel M., McNeill P.M., Carlson P.L., et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991, 87:1787-1793.
344. Lindblad B., Wakefield T.W., Whitehouse W.M., et al. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg 1988, 22:55-58.
345. Gimple L.W., Gold H.K., Leinbach R.C., et al. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarcation with recombinant tissue-type plasminogen activator. Circulation 1989, 80:581-588.
346. Coller B.S. Platelets and thrombolytic therapy. N Engl J Med 1990, 322:33-42.
347. Schafer A.I., Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985, 75:456-461.
348. Schafer A.I., Maas A.K., Ware J.A., et al. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 1986, 78:73-79.
349. Penny W.F., Ware J.A. Platelet activation and subsequent inhibition by plasmin and recombinant tissuetype plasminogen activator. Blood 1992, 79:91-98.
350. Loscalzo J., Vaughan D.E. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987, 79:1749-1755.
351. Quinton T.M., Kim S., Derian C.K., et al. Plasminmediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 2004, 279:18434-18439.
352. Fitzgerald D.J., Catella F., Roy L., et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988, 77:142-150.
353. Kerins D.M., Roy L., Fitzgerald G.A., et al. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 1989, 80:1718-1725.
354. Mills D.C.B., Roberts G.C.K. Membrane active drugs and the aggregation of human blood platelets. Nature 1967, 213:35.
355. Mills D.C.B., Robb I.A., Roberts G.C.K. The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation. J Physiol 1968, 195:715-729.
356. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: A platelet connection. Cell Mol Life Sci 2005, 62:159-170.
357. Humphries J.E., Wheby M.S., Van den Berg S.R. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990, 114:727-728.
358. Alderman C.P., Moritz C.K., Ben-Tovim D.I. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother 1992, 26:1517-1519.
359. Hergovich N., Aigner M., Eichler H.G., et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000, 68:435-442.
360. Rysanek R., Svehla C., Spankova H., et al. The effect of tricyclic antidepresive drugs on adrenaline and adenosine diphosphate induced platelet aggregation. J Pharmacol Exp Ther 1966, 18:616.
361. O'Brien J.R. The adhesiveness of native platelets and its prevention. J Clin Pathol 1961, 14:140.
362. Jain M.F., Eskow E., Kuchibhotla J., et al. Correlation of inhibition of platelet aggregation by phenothiazines and local anesthetics with their effects on a phospholipid bilayer. Thromb Res 1978, 13:1067-1075.
363. White G.C., Raynor S.T. The effects of trifluoroperazine, an inhibitor of calmodulin on platelet function. Thromb Res 1980, 18:279-284.
364. Warlow C., Ogston D., Douglas A.S. Platelet function after administration of chloropromazine to human subjects. Haemostasis 1976, 5:21-26.
365. Dalsgaard-Nielsen J., Risbo A., Simmelkjaer P., et al. Impaired platelet aggregation and increased bleeding time during general anesthesia with halothane. Br J Anaesth 1981, 53:1039-1042.
366. Corbin F., Blaise G., Sauve R. Differential effect of halothane and forskolin on platelet cytosolic Ca2+ mobilization and aggregation. Anesthesiology 1998, 89:401-410.
367. Parolari A., Guarnieri D., Alamanni F., et al. Platelet function and anesthetics in cardiac surgery: An in vitro and ex vivo study. Anesth Analg 1999, 89:26-31.
368. Langdell R.D., Adelson E.A., Furth F.W. Dextran and prolonged bleeding time. J Am Med Assoc 1958, 166:346.
369. Ewald R.A., Eichelberger J.W., Young A.A., et al. The effect of dextran on platelet factor 3 activity: In vitro and in vivo studies. Transfusion 1965, 5:109.
370. Bygdeman S., Eliasson R. Effect of dextrans on platelet adhesiveness and aggregation. Scand J Clin Lab Invest 1967, 20:17-23.
371. Weiss H.J. The effect of clinical dextran on platelet aggregation, adhesion and ADP release in man: In vivo and in vitro studies. J Lab Clin Med 1967, 69:37-46.
372. Evans R.J., Gordon J.D. Mechanisms of the antithrombotic action of dextran. N Engl J Med 1974, 290:748.
373. Mishler J.M. Synthetic plasma volume expanders -Their pharmacology, safety and clinical efficacy. Clin Haematol 1984, 13:75-92.
374. Aberg M., Hedner U., Bergentz S.E. Effect of dextran 70 on factor VIII and platelet function in von Willebrand's disease. Thromb Res 1978, 12:629-634.
375. Kelton J.G., Hirsch J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980, 17:259-291.
376. Gruber U.F., Saldeen T., Brokop T., et al. Incidences of fatal postoperative pulmonary embolism after prophylaxis with dextran 70 and low-dose heparin: An international multicentre study. Br Med J 1980, 280:69-72.
377. Roberts J.S., Bratton S.L. Colloid volume expanders. Problems, pitfalls and possibilities. Drugs 1998, 55:621-630.
378. Cope J.T., Banks D., Mauney M.C., et al. Intraoperative hetastarch infusion impairs hemostasis after cardiac operations. Ann Thorac Surg 1997, 63:78-82.
379. Ruttmann T.G., James M.F., Aronson I. In vivo investigation into the effects of haemodilution with hydroxyethyl starch (190/0.5) and normal saline on coagulation. Br J Anaesth 1998, 80:612-616.
380. Favis G.R., Colman R.W. The action of halofenate on platelet shape change and prostaglandin synthesis. J Lab Clin Med 1978, 92:45-52.
381. Colman R.W., Bennett J.S., Sheridan J.S., et al. Halofenate: A potent inhibitor of normal and hypersensitive platelets. J Lab Clin Med 1976, 88:282-291.
382. Klener P., Kubisz P., Suranova J. Influence of cytotoxic drugs on platelet functions and coagulation in vitro. Thromb Haemostas 1977, 37:53-61.
383. Pogliani E.M., Fantasia R., Lambertenghi-Deliliers G., et al. Daunorubicin and platelet function. Thromb Haemost 1981, 45:38-42.
384. Kubisz P., Klener P., Gronberg S. Influence of mithramycin on some platelet functions in vitro. Acta Haematol 1980, 63:101-106.
385. Ahr D.J., Scialla S.J., Kimball D.B. Acquired platelet dysfunction following mithramycin therapy. Cancer 1978, 41:448-454.
386. McKenna R., Ahmad T., Ts'ao C.H., et al. Glutathione reductase deficiency and platelet dysfunction induced by 1,, 3-bis (2-chloroethyl) -1-nitrosourea. J Lab Clin Med 1983, 102:102-115.
387. Karolak L., Chandra A., Khan W., et al. Highdose chemotherapy-induced platelet defect: Inhibition of platelet signal transduction pathways. Mol Pharmacol 1993, 43:37-44.
388. Thomson C., Forbes C.D., Prentice C.R.M. A comparison of the effects of antihistamines on platelet function. Thromb Diath Haemorrh 1973, 30:547-556.
389. Herrmann R.G., Frank J.D. Effect of adenosine derivatives and antihistamines on platelet aggregation. Proc Soc Exp Biol Med 1966, 123:654-660.
390. Green D., Ts'ao C.H., Cerullo L., et al. Clinical and laboratory investigation of the effects of E-aminocaproic acid on hemostasis. J Lab Clin Med 1985, 105:321-327.
391. Rubin R., Rand M.L. Alcohol and platelet function. Alcohol Clin Exp Res 1994, 18:105-110.
392. Rand M.L., Packham M.A., Kinlough-Rathbone R.L., et al. Effects of ethanol on pathways of platelet aggregation in vitro. Thromb Haemost 1988, 59:383-387.
393. Mikhailidis D.P., Barradas M.A., Jeremy J.Y. The effect of ethanol on platelet function and vascular prostanoids. Alcohol 1990, 7:171-180.
394. Deykin D., Janson P., McMahon L. Ethanol potentiation of aspirin-induced prolongation of the bleeding time. N Engl J Med 1982, 306:852-854.
395. Rao A.K., Rao V.M., Willis J., et al. Inhibition of platelet function by contrast media. Iopamidol and Hexabrix are less inhibitory then
396. Li X., Gabriel D.A. Differences between contrast media in the inhibition of platelet activation by specific platelet agonists. Acad Radiol 1997, 4:108-114.
397. Parvez Z., Moncada R., Fareed J., et al. Antiplatelet action of intravascular contrast media. Implications in diagnostic procedures. Invest Radiol 1984, 19:208-211.
398. Grabowski E.F., Jang I.K., Gold H., et al. Variability of platelet degranulation by different contrast media. Acad Radiol 1996, 3 (Suppl. 3:S485-S487.
399. Jandak J., Steiner M., Richardson P.D. α-Tocopherol, an effective inhibitor of platelet adhesion. Blood 1989, 73:141-149.
400. Steiner M., Anastasi J. Vitamin E. An inhibitor of the platelet release reaction. J Clin Invest 1976, 57:732-737.
401. Goodnight S.H. Effects of dietary fish oil and omega-3 fatty acids on platelets and blood vessels. Semin Thromb Hemost 1988, 14:285-289.
402. Srivastava K.C. Onion exerts antiaggregatory effects by altering arachidonic acid metabolism in platelets. Prostaglandins Leukotr Med 1986, 24:43-50.
403. Phillips C., Poyser N.L. Inhibition of platelet aggregation by onion extracts. Lancet 1978, 1:1051-1052.
404. Makheja A.N., Vanderhock J.Y., Bailey J.M. Inhibition of platelet aggregation and thromboxane synthesis by onion and garlic. Lancet 1979, 1:781.
405. Bordia A., Verma S.K., Srivastava K.C. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukotr Essent Fatty Acids 1998, 58:257-263.
406. Bordia A., Verma S.K., Srivastava K.C. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigo- nella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukotr Essent Fatty Acids 1997, 56:379-384.
407. Srivastava K.C. Extracts from two frequently consumed spices -cumin (Cuminum cyminum) and turmeric (Curcuma longa) -inhibit platelet aggregation and alter eicosanoid biosynthesis in human blood platelets. Prostaglandins Leukotr Essent Fatty Acids 1989, 37:57-64.
408. Srivastava K.C., Bordia A., Verma S.K. Curcumin, a major component of food spice turmeric (Curcuma longa) , inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukotr Essent Fatty Acids 1995, 52:223-227.
409. Srivastava K.C. Antiplatelet principles from a food spice clove (Syzygium aromaticum L). Prostaglandins Leukotr Essent Fatty Acids 1993, 48:363-372.
410. Pearson sD.A., Paglieroni T.G., Rein D., et al. The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Thromb Res 2002, 106:191-197.
411. Dorso C.R., Levin R.I., Eldor A., et al. Chinese food and platelets. N Engl J Med 1980, 303:756-757.
412. Hammerschmidt D.E. Szechwan purpura. N Engl J Med 1980, 302:1191-1193.
413. Fugh-Berman A. Herb-drug interactions. Lancet 2000, 355:134-138.